APA (7th ed.) Citation

T, K., M, S., DM, F., S, G., JP, S. V., HC, S., . . . JM, L. (2024). Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Journal of neuroendocrinology, 36(1), e13360. https://doi.org/10.1111/jne.13360

Chicago Style (17th ed.) Citation

T, Krishnan, Safro M, Furlanetto DM, Gill S, Solar Vasconcelos JP, Stuart HC, Martineau P, and Loree JM. "Clinical Impact of Unsuccessful Subcutaneous Administration of Octreotide LAR Instead of Intramuscular Administration in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors." Journal of Neuroendocrinology 36, no. 1 (2024): e13360. https://doi.org/10.1111/jne.13360.

MLA (9th ed.) Citation

T, Krishnan, et al. "Clinical Impact of Unsuccessful Subcutaneous Administration of Octreotide LAR Instead of Intramuscular Administration in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors." Journal of Neuroendocrinology, vol. 36, no. 1, 2024, p. e13360, https://doi.org/10.1111/jne.13360.